Acquired MET amplification accounts for 5–24% of the EGFR TKI-resistant cases, while de novo MET amplification accounts for approximately 3% of EGFR-mutated NSCLC patients before treatment [17, 18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.